NTRA:NSD-Natera Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 140.02

Change

+7.39 (+5.57)%

Market Cap

USD 21.03B

Volume

2.22M

Analyst Target

USD 56.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-11 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

-9.79 (-2.24%)

USD 35.55B
ICLR ICON PLC

-6.94 (-3.80%)

USD 16.66B
ILMN Illumina Inc

-1.45 (-1.69%)

USD 14.06B
MEDP Medpace Holdings Inc

-11.54 (-3.42%)

USD 9.97B
EXAS EXACT Sciences Corporation

+0.92 (+2.05%)

USD 9.13B
GH Guardant Health Inc

+6.79 (+18.95%)

USD 4.85B
RDNT RadNet Inc

+1.18 (+2.46%)

USD 4.54B
SHC Sotera Health Co

-0.43 (-3.64%)

USD 3.91B
VCYT Veracyte Inc

+0.72 (+2.37%)

USD 3.18B
WGS GeneDx Holdings Corp.

-2.49 (-2.78%)

USD 2.75B

ETFs Containing NTRA

GN0M:XETRA Global X Genomics & Biote.. 6.31 % 0.00 %

-0.20 (-1.31%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 6.31 % 0.00 %

-0.17 (-1.31%)

USD 9.42M
CURG:LSE VanEck Genomics and Healt.. 5.94 % 0.00 %

-0.39 (-1.31%)

USD 5.16M
GNOG:LSE Global X Genomics & Biote.. 5.72 % 0.00 %

-0.15 (-1.31%)

USD 9.42M
GNOM Global X Genomics & Biote.. 5.66 % 0.00 %

+0.04 (+-1.31%)

USD 0.06B
ARCG:LSE ARK Genomic Revolution UC.. 5.44 % 0.00 %

-3.88 (-1.31%)

USD 9.51M
EKG First Trust Nasdaq Lux Di.. 5.37 % 0.00 %

+0.06 (+-1.31%)

USD 2.77M
ARKG:LSE ARK Genomic Revolution UC.. 4.97 % 0.00 %

-0.05 (-1.31%)

USD 9.33M
CURE:XETRA VanEck Genomics and Healt.. 4.55 % 0.00 %

-0.54 (-1.31%)

N/A
WRNA:XETRA WisdomTree BioRevolution .. 4.37 % 0.00 %

-0.37 (-1.31%)

USD 2.77M
WBIO:LSE WisdomTree BioRevolution .. 4.25 % 0.00 %

-24.30 (-1.31%)

USD 4.20M
WDNA WisdomTree BioRevolution .. 4.14 % 0.00 %

+0.05 (+-1.31%)

USD 2.22M
ATFV Alger 35 ETF 3.88 % 0.00 %

+0.34 (+-1.31%)

USD 0.03B
CURE:AU ETFS S&P Biotech ETF 2.35 % 0.00 %

+0.26 (+-1.31%)

USD 0.04B
WDNA:LSE WisdomTree BioRevolution .. 2.31 % 0.00 %

-0.27 (-1.31%)

N/A
HEAL:SW iShares Healthcare Innova.. 2.30 % 0.00 %

-0.07 (-1.31%)

USD 1.05B
ZHU:CA BMO Equal Weight US Healt.. 1.97 % 0.00 %

-0.43 (-1.31%)

CAD 0.01B
DOCT:SW L&G Healthcare Breakthrou.. 1.86 % 0.00 %

-0.17 (-1.31%)

USD 0.07B
DOCG:LSE L&G Healthcare Breakthrou.. 1.85 % 0.00 %

-23.55 (-1.31%)

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 1.85 % 0.00 %

-0.27 (-1.31%)

USD 0.07B
XMLH:F Legal & General Ucits Etf.. 1.80 % 0.00 %

-0.09 (-1.31%)

N/A
EQQJ:XETRA Invesco NASDAQ Next Gener.. 1.38 % 0.00 %

-1.04 (-1.31%)

USD 0.05B
FSMD Fidelity Small-Mid Factor 0.39 % 0.00 %

-0.01 (-1.31%)

USD 0.86B
VISM:AU Vanguard MSCI Internation.. 0.26 % 0.00 %

-0.63 (-1.31%)

USD 0.29B
ZPRS:F SSgA SPDR ETFs Europe II .. 0.25 % 0.00 %

N/A

USD 0.83B
WOSC:SW SPDR® MSCI World Small C.. 0.25 % 0.00 %

-0.61 (-1.31%)

USD 1.06B
ARKG ARK Genomic Revolution ET.. 0.00 % 0.75 %

+0.46 (+-1.31%)

USD 1.32B
BBH VanEck Biotech ETF 0.00 % 0.35 %

-3.22 (-1.31%)

USD 0.39B
FHH:CA First Trust AlphaDEX US H.. 0.00 % 0.77 %

-0.19 (-1.31%)

CAD 0.01B
IBB iShares Biotechnology ETF 0.00 % 0.47 %

-1.85 (-1.31%)

USD 6.39B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

-0.40 (-1.31%)

USD 0.77B
PTH Invesco DWA Healthcare Mo.. 0.00 % 0.60 %

+0.46 (+-1.31%)

USD 0.13B
BTEC 0.00 % 0.42 %

N/A

N/A
VBK Vanguard Small-Cap Growth.. 0.00 % 0.07 %

-0.01 (-1.31%)

USD 20.34B
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

-1.15 (-1.31%)

CAD 0.22B
WLDS:LSE iShares MSCI World Small .. 0.00 % 0.00 %

-0.10 (-1.31%)

N/A
WSML:LSE iShares MSCI World Small .. 0.00 % 0.00 %

-0.11 (-1.31%)

N/A
IS0R:F iShares High Yield Corpor.. 0.00 % 0.00 %

-1.04 (-1.31%)

N/A
2B78:XETRA iShares Healthcare Innova.. 0.00 % 0.00 %

-0.21 (-1.31%)

USD 1.14B
IS0R:XETRA iShares $ High Yield Corp.. 0.00 % 0.00 %

-0.92 (-1.31%)

N/A
IUSN:XETRA iShares MSCI World Small .. 0.00 % 0.00 %

-0.14 (-1.31%)

N/A
ZPRS:XETRA SPDR MSCI World Small Cap.. 0.00 % 0.00 %

-1.97 (-1.31%)

N/A
XMLH:XETRA L&G Healthcare Breakthrou.. 0.00 % 0.00 %

-0.31 (-1.31%)

N/A
BBMC JPMorgan BetaBuilders U.S.. 0.00 % 0.00 %

-0.26 (-1.31%)

USD 1.80B
FRTY Alger Mid Cap 40 ETF 0.00 % 0.00 %

+0.23 (+-1.31%)

USD 0.09B
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

-0.13 (-1.31%)

N/A
CVRT Calamos ETF Trust 0.00 % 0.00 %

+1.24 (+-1.31%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.55% 63% D 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.55% 63% D 38% F
Trailing 12 Months  
Capital Gain 54.19% 85% B 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 54.19% 85% B 91% A-
Trailing 5 Years  
Capital Gain 394.60% 100% F 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 394.60% 100% F 95% A
Average Annual (5 Year Horizon)  
Capital Gain 48.04% 83% B 87% B+
Dividend Return 48.04% 83% B 87% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 88.73% 38% F 23% F
Risk Adjusted Return 54.14% 94% A 80% B-
Market Capitalization 21.03B 98% N/A 96% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.